When Bristol-Myers Squibb kicked off 2019 by making a $74 billion?bid?for Celgene, biopharma watchers everywhere declared it to be the?end?of the mergers-and-acquisitions drought in the sector.
After two recent, huge tie-ups between Takeda and Shire and Bristol-Myers Squibb and Celgene, megamergers seem to be a biopharma trend. But Roche isn't interested in it, its chairman said.